Skip to main content

We’re thrilled to share our new look with you! Some features are still being fine-tuned. Thank you for your patience as we enhance your experience.

Main navigation

    • About
    • Leadership
    • Operations
    • Network Groups & Committees
    • Network Spotlights
    • Funding Acknowledgements
    • Studies
    • Sites
    • Publications
    • Public Data Sets
    • Specific Aims
    • Presented Research
    • HPTN Scholars Program
    • Submit a Research Idea
    • Ancillary Study Application
    • Community Engagement Program
    • Study Populations
    • Engagement Toolbox
    • Educational Resources
    • HPTN Black Caucus
    • Meetings & Events
    • Manual of Procedures
    • Resources and Forms
    • HPTN Brand Guide and Templates
    • Regulatory Resources
    • External Resources
    • Research Tools
    • COVID-19
    • Press Releases
    • Announcements
    • Featured Stories
    • Meetings & Events
    • Newsletters
    • Key Contacts
    • Directory
    • Email Lists
    • Press
Event

CROI 2024

Mar 3-6, 2024
Denver, USA

HPTN Presentations at CROI 2024

The HPTN presented research at CROI 2024, the Conference on Retroviruses and Opportunistic Infections.

 

  • 00131 - Cabotegravir Maintains Protective Efficacy in the Setting of Bacterial STIs: HPTN 083
  • 0789 - No Increased Risk for Hypertension With CAB-LA Compared to TDF/FTC for HIV PrEP in HPTN 083
  • 00128 - Site-Based HIV Testing Assay Performance for Cabotegravir and TDF-FTC PrEP Failure in HPTN 083

HPTN NEWSLETTER

Subscribe to our monthly newsletter and stay connected to HPTN.

QUICK LINKS

Directory Studies MOP
FHI 360 logo © 2025 HPTN

Footer

  • Privacy Notice
  • Cookie Notice
  • Contact
  • Terms of Use